Skip to main content
. 2022 Mar 9;81(5):653–661. doi: 10.1136/annrheumdis-2021-221865

Figure 2.

Figure 2

Trial profile. Not all patients who discontinued treatment withdrew from the trial; two patients receiving mavrilimumab and two patients receiving placebo withdrew before week 26, and one patient receiving mavrilimumab withdrew between week 26 and week 38.